Metabolism of iron stores

Nagoya Journal of Medical Science

Volumn 76, Issue 3-4, 2014, Pages 235-254

  Saito, Hiroshi ^a  

^a Kawamura Hospital   (Japan)

Author keywords

Ferritin and hemosiderin; Iron deficiency and overload; Serum ferritin kinetics; Storage iron turnover

Indexed keywords

EID: 84906667443     PISSN: 00277622     EISSN: 21863326     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Bothwell TH et al. Clinical estimation of body iron stores. In: Iron metabolism in man. Clinical estimation of body iron stores; pp 88-93. Internal iron kinetics; pp 327-349, 1979. Edited by Bothwell TH, Charlton R, Cook JD and Finch CA. Blackwell Scientific Publications, Oxford London Edinburgh Melbourne.
2. Shoden A, Gabrio BW, Finch CA. The relationship between ferritin and hemosiderin in rabbits and man. J Biol Chem, 1953; 204(2): 823-830.
3. Sturgeon P, Shoden A. Mechanism of iron storage. In: Iron metabolism. pp 121-146, 1964. An international symposium sponsored by CIBA at Aix-en-Provence, 1963. Edited by Gross F. Springer-Verlag Berlin, Göttingen, Heidelberg.
4. Saito H, Tomita A, Ohashi H, Maeda H, Hayashi H, Naoe T. Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics. Nagoya J Med Sci, 2012; 74(1-2): 39-49.
5. Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood, 1976; 48(3): 449-455.
6. Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. Blood, 1986; 68(3): 726-731.
7. Uchida T. Anemia in Japanese women: the current situation and the cause. Rinsho Ketsueki (Jpn J Clin Hematol), 2004; 45(10): 1085-1089. (in Japanese)
8. Saito H, Ishikawa K. Ferritin. Nippon-Rinsho (Jpn J Clin Med), 1985; 532(1): 122-125. (in Japanese)
9. Fleming RE, Bacon BR. Perspective. Orchestration of iron homeostasis. New Engl J Med, 2005; 352(17): 1741-1744.
10. Matioli GT, Baker RF. Determination of ferritin and its relationship with hemosiderin. J Ultrastruct Res, 1963; 8(5-6): 477-490.
11. Miyazaki E, Kato J, Kobune M, Okumura K, Nishitani N, Arosio P, Niitsu Y. Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload. Gut, 2002; 50(3): 413-419.
12. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med, 2002; 32(9): 833-840.
13. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. New Engl J Med, 1988; 319(16): 1047-1052.
14. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J, 1989; 76(5): 1177-1188.
15. Hayashi H, Takikawa T, Nishimura N, Yano T, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess iron. Am J Gastroenterol, 1994; 89(7): 986-988.
16. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda M. Familial apoceruloplasmin deficiency associated with blephalospasm and retinal degeneration. Neurology, 1987; 37(5): 761-767.
17. Toyokuni S. Mysterious link between iron overload and CDKN2A/2B. J Clin Biochem Nutr, 2011; 48(1): 46-49.
18. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa A, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once a daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006; 107(9): 3455-3462.
19. Krause A, Nietz S, Magert HJ, Schultz A, Forssmann WG, Schultz-Knappe P, Adermann K. LEAP (liverexpressed antimicrobial peptide) -1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS (Federation of European Biochemical Societies) Letters, 2000; 480(2-3): 147-150.
20. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA, 2001; 98 (15): 8780-8785.
21. Saito H, Hayashi H, Tomita A, Ohashi H, Maeda H, Naoe T. Increasing and decreasing phases of ferritin and hemosiderin iron determined by serum ferritin kinetics. Nagoya J Med Sci, 2013; 76(3-4): 213-223.
22. Haskins D, Stevens AR Jr, Finch SC, Finch CA. Iron metabolism; iron stores in man as measured by phlebotomy. J Clin Invest, 1952; 31(6): 543-547.
23. Milder MS, Cook JD, Finch CA. Idiopathic hemochromatosis: an interim report. Medicine, 1980; 59(1): 34-49.
24. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver disease. Gastroenterol, 1975; 68(3): 521-533.
25. van Oost BA, van den Beld B, van Ashbeck BS, Marx JJM. Monitoring of intensive phlebotomy therapy in iron overload by serum ferritin assay. Am J Hematol, 1985; 18(1): 7-12.
26. Saito H, Kawamura Y. Storage iron decrease rates and their clinical significance in iron deficiency anemia patients following intravenous iron therapy. Rinsho Ketsueki (Jpn J Clin Hematol), 1999; 40(12): 112-118. (in Japanese)
27. Saito H, Maeda H. Method for determining the amount of blood loss using the storage iron decrease rate as obtained from serum ferritin after intravenous iron therapy. Rinsho Ketsueki (Jpn J Clin Hematol), 2004; 45(11): 1177-1180. (in Japanese)
28. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Brit J Haemat, 1994; 87(1): 171-184.
29. Angellucci E, Giovagnoni A, Valeri G, Paci E, Ripalti M, Muretto P, McLaren C Brittenham GM, Lucarelli G. Limitation of magnetic resonance imaging in measurement of hepatic iron. Blood, 1997; 90(12): 4736-4742.
30. Addison SM, Biemish MR, Hales CN, Hodgkins M, Jacobs A, Llewellin P. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. J Clin Pathol, 1972; 25(4): 326-329.
31. Cook JD, Lipschitz DA, Miles EM, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr, 1974; 27(7): 681-687.
32. Jacobs A, Worwood M. Ferritin in serum. Clinical and biological implications. New Engl J Med, 1975; 292(18): 951-958.
33. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol, 1973; 26(10): 770-772.
34. Beaumont C, Leneuve P, Devaux I, Scoazec J-Y, Berthier M, Loiseau M-N, Grandchamp B. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet, 1995; 11(4): 444-446.
35. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood, 2003; 101(9): 3347-3350.
36. Williams R, Manenti F, Williams HS, Pitcher CS. Iron absorption in idiopathic haemochromatosis before, during, and after venesection therapy. Brit Med J, 1966; 2(5505): 78-81.
37. Sargent T, Saito H, Winchell HS. Increased iron absorption in hemochromatosis before and after phlebotomy therapy. J Nucl Med, 1971; 12(10): 660-667.
38. Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood, 2004, 103(12): 4669-4671
39. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. "Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis". Nat Genet, 2003, 33(1): 21-22.
40. Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D, Butterfield Y, Rodrigues P, Jones S, Porto G, Marra M, De Sousa M, Vatcher G. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood, 2002; 100(3): 1075-1077.
41. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, Calì A, De Gobbi M, Gasparini P, Camaschella C. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood, 2001; 97(9): 2555-2560.
42. Pelucchi S, Mariani R, Trombini P, Coletti S, Pozzi M, Paolini V, Barisani D, Piperno A. Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2. Haematol, 2009; 94(2): 276-279.
43. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest, 2001; 108(4): 619-623.
44. Koyama C, Wakuzawa S, Hayashi H, Ueno T, Suzuki R, Yano M, Saito H, Okazaki T. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene; Hyperferritinemia associated with a relatively low transferrin saturation of iron. Int Med, 2005; 4(9): 990-993.
45. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis, 2004; 32(1): 131-138.
46. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in ß-thalassemic mice. J Clin Invest, 2010; 120(12): 4466-4477.
47. Heilmeyer L, Keller W, Vivell O, Keiderling W, Betke K, Wöhler F, Schultze H. Congenital atransferrinemia in a 7-year-old girl. Deu Med Wochenschr, 1946; 86(37): 1745-1751.
48. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. "Molecular characterization of a case of atransferrinemia". Blood, 2000; 96 (13): 4071-4074.
49. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1. Blood, 2006; 107(1): 349-354.
50. Beaumont C, Delaunay J, Hetet G, Grandchamp B, de Montalembert M, Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood, 2006; 107(10): 4168-4170.
51. Martini LA, Tchack L, Wood RJ. Iron treatment downregurates DMT1 and IREG1 mRNA expression in Caco-2 cells. J Nutr, 2002; 132(4): 693-696.
52. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes, 2002; 51(8): 2348-2354.
53. Bessis MC, Breton-Gorius J. Iron metabolism in the bone marrow as seen by electronmicroscopy. A critical review. Blood, 1962; 19(6): 635-663.
54. Zail SS, Charlton RW, Torrance JD, Bothwell TH. Studies on the formation of ferritin in red cell precursors. J Clin Invest, 1964; 43(4): 670-680.
55. Cazzola M, Dezza L, Bergamaschi G, Barosi G, Bellotti V, Caldera D, Criello MM, Cuaglini S, Arosio P, Ascari E. Biologic and clinical significance of red cell ferritin. Blood, 1983; 62(5): 1078-1087.
56. Saito H, Sargent T, Parker HG, Lawrence JH. Whole body iron loss in normal man measured with a gamma spectrometer. J Nucl Med, 1964; 5(8): 571-580.
57. Green R, Charlton RW, Seftel H, Bothwell T, Mayer F, Adams B, Finch CA, Layrisse M. Body iron excretion in man. A collaborative study. Am J Med, 1968; 45(3): 336-353.
58. Granick S. Ferritin. Its properties and significance for iron metabolism. Chem Rev, 1946; 38(3): 379-403.
59. Saito H. Studies on storage iron. Dynamic behavior of ferritin and hemosiderin under various experimental conditions. Nagoya J Med Sci, 1958; 21(4): 288-300.
60. Miura T. Iron excretion into feces in various hematological disorders. Jpn J Radiol, 1968; 28(9): 1288-1295. (in Japanese)
61. Breuer W, Shvartsman M, Cabantchik ZI. Intracellular labile iron. Int J Biochem Cell Biol, 2008; 40(3): 350-354.
62. Conrads ME, Crosby WH. Intestinal mucosal mechanisms controlling iron absorption. Blood, 1963; 22(4): 406-415.
63. Saito H. In: Clinical disorders of iron metabolism-from iron deficiency to iron overload, Ferrokinetics; pp 24-28, Iron absorption in iron deficiency states; pp 36-39, 1999, Edited by Saito H. Iyaku Journal, Ltd., Osaka, Japan. (in Japanese)
64. Shiono Y, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Yano M, Yoshioka K, Saito H. Body iron stores and iron restoration rate in Japanese patients with chronic hepatitis C as measured during therapeutic iron removal revealed neither increased body iron stores nor effects of C282Y and H63D mutations on iron indices. Nagoya J Med Sci, 2001; 64(1-2): 5-7.
65. Nemeth E, Tuttle MS, Powelson J, Baughn MB, Donovan A, Ward DM, Gantz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004; 306(5704): 2090-2093.
66. Ganz T, Brissot P, Cohen AR. Iron in hematology. Hepcidin and its role in regulating systemic iron metabolism. Am Soc of Hematol (ASH) Education Book, 2006; 2006(1): 29-35.
67. Hadley KB, Johnson LK, Hunt JL. Iron absorption by healthy women is not associated with either serum or urine prohepcidin1-4. Am J Clin Nutr, 2006; 84(1): 150-155.
68. Fraser DM, Anderson GJ. Hepcidin compared with prohepcidin: an absorbing story. Am J Clin Nutr, 2009; 89(1): 475-476.
69. Trombini P, Coliva T, Nemeth E, Mariani R, Ganz T, Bionidi A, Piperno A. Effects of plasma transfusion on hepcidin production in human congenital atransferrinemia. Haematol, 2007; 92(10): 1407-1410.
70. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood, 2006; 108(12): 3730-3735.
71. Feder JN, Gnike A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F Domingo RJr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel E, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McCleland E, Meyer NC, Mintier GA, Moeller N, Moor T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drevna DT, Risch NJ, Bacon BR, WolffRK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 1996; 13 (4): 399-408.
72. Koyama C, Hayashi H, Wakusawa S, Ueno T, Yano M, Katano Y, Goto H, Kidokoro R. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol, 2005, 43(4):740-742.
73. Zhang AS. Control of systemic iron homeostasis by the hemojuvelin-hepcidin axis. Adv Nutr, 2010; 1(11): 38-45.
74. Distante S, Berg JP, Lande K, Haug E, Bella H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut, 2000; 47(4): 575-579.
75. Galy B, Ferring-Appel D, Becker C, Gretz N, Grone HJ, Schumann K, Hentze MW. Iron regulatory proteins control a mucosal block to intestinal iron absorption. Cell Rep, 2013; 28(3): 844-857.
76. Beutler E, Felitti V, Gelbart T, Ho N. Genetics of iron storage and hemochromatosis. Drug Metab Dispos, 2001; 29(4): 495-499.
77. Keast D, Sheppard NP, Papadimitriou JM. Some biological properties of respirable iron ore dust. Environ Res, 1987; 42(2): 455-468.
78. Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord, 2006; 21(9): 1299-1310.
79. Gregory A, Hayflick SJ. Genetics of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep, 2011; 11(3): 254-261.
80. Curtis AR, Fey C, Morris CM, BindoffLA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet, 2001; 28(4): 350-354.
81. Beard J. Iron deficiency alters brain development and functioning. J Nutr, 2003; 133(5 suppl 1): 468S-472S.
82. Finch S, Haskins D, Finch CA. Iron metabolism. Hematopoiesis following phlebotomy. Iron as a limiting factor. J Clin Invest, 1950; 29(8): 1078-1086.
83. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, Kawano Y, Takahashi S, Takahashi M, Sato Y, Takayama T, Niitsu Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol, 2007; 42(10): 830-836.
84. Saito H. Suppression of thyroid function by iron deficiency anemia in patients with hyperthyroidism. Jpn J Nucl Med, 1977; 14(2): 291-295. (in Japanese)
85. Finberg, KE. Iron-refractory iron deficiency anemia. Sem in Hematol, 2009; 46(4): 378-386.
86. Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood, 2006; 107(4): 1673-1679.
87. Crosby WH. Treatment of hemochromatosis by energetic phlebotomy. One patient's response to the letting of 55 litres of blood in 11 months. Brit J Haemat, 1958; 4(1): 82-88.
88. Hillman RS, Henderson PA. Control of marrow production by relative iron supply. J Clin Invest, 1969; 48(3): 454-460.
89. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 2003; 102(3): 783-788.
90. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood, 2006; 107(7): 2702-2704.
91. Theurl I, Finkensted A, Schroll A, Nairz M, Sonnweber T, Bellmann-Weiler R, Theurl M, Seifert M, Wroblewski VJ, Murphy AM, Witcher D, Zoller H, Weiss G, Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Brit J Haemat, 2009; 148(3): 449-455.
92. Fineberg RA, Greenberg DM. Ferritin biosynthesis. II. Acceleration of synthesis by administration of iron. J Biol Chem, 1956; 214(1): 97-106.
93. Coulson RM, Cleveland DW. Ferritin synthesis is controlled by iron-dependent translational derepression and by changes in synthesis/transport of nuclear ferritin RNAs. Proc Natl Acad Sci USA, 1993; 90(16): 7613-7617.
94. De Domenico I., Ward D. M., Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood, 2009; 114(20): 4546-4551.
95. Goralska M, Nagar S, Lloyd N. Fleisher LN, McGahan MC. Differential degradation of ferritin H- and L-chains: Accumulation of L-chain-rich ferritin in lens epithelial cells. Invest Ophthalmol Vis Sci, 2005; 46(10): 3521-3529.
96. Hentze MW, Kuhnt LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA, 1996; 93(16): 8175-8182.
97. Eisenstein RS, Blemings KP. Iron regulatory proteins, iron responsive elements and iron homeostasis. J Nutr, 1998; 128(12): 2295-2298.
98. Thomson AM, Rogers JT, Leedman PJ. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol, 1999; 31(10): 1139-1152.
99. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter H, McPhee J, Sarang SS, Utsuk T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. An iron-responsive element type II in the 5-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem, 2002; 277(47): 45518-45528.
100. Arosio C, Fossati L, Vigano M, Trombini P, Cazzaniga G, Piperno A: Hereditary hyperferritinemia cataract syndrome: a de novo mutation in the iron responsive element of the L-ferritin gene. Haematol, 1999; 84(6): 560-561.
101. Nonnenmacher L, Langer T, Blessing H, Gabriel H, Buchwald HJ, Meneksedag C, Kohne E, Gencik M, Debatin KM, Cario H. Hereditary hyperferritinemia cataract syndrome: clinical, genetic, and laboratory findings in 5 families. Klin Pädiatr, 2011; 223(6): 346-351.
102. Fillet G, Cook JD, Finch CA. Storage iron kinetics. VII. A biologic model for reticuloendothelial iron transport. J Clin Invest, 1974; 53(6): 1527-1533.
103. Finch CA. Body iron exchange in man. J Clin Invest, 1959; 38(2): 392-396.
104. HuffRL, Hennessy TG, Austin RE, Garcia JF, Roberts BM, Lawrence JH. Plasma and red cell iron turnover in normal subjects and in patients having various hematopoietic disorders. J Clin Invest, 1950; 29(8): 1041-1052.
105. HuffRL, Elmlinger PJ, Garcia JF, Oda JM, Cockrell MC, Lawrence JH. Ferrokinetics in normal persons and in patients having various erythropoietic disorders. J Clin Invest, 1951; 30(12): 1512-1526.
106. Saito H, Yamada H. Studies on red cell production and destruction in various hematological disorders in view of ferrokinetics. Acta Haem Jap, 1973; 36(5): 109-137.
107. Pollycove M, Mortimer R. The quantitative determination of iron kinetics and hemoglobin synthesis in human subjects. J Clin Invest, 1961; 40(5): 753-782.
108. Hosain F, Marsaglia G, Finch CA. Blood kinetics in man. J Clin Invest, 1967; 46(1): 1-9.
109. Cook JD, Marsaglia G, Eschbach JW, Funk DD, Finch CA. Ferrokinetics: a biologic model for plasma iron exchange in man. J Clin Invest, 1970; 49(2): 197-205.
110. Liu Q, DavidoffO, Niss K and Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietininduced erythropoiesis. J Clin Invest, 2012; 122(12): 4635-4644.